Annuncio • Dec 05
Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.
Security Name: Ordinay Shares
Security Type: Common Stock
Securities Offered: 120,395,238
Price\Range: AUD 0.0115
Discount Per Security: AUD 0.00069
Security Name: Ordinay Shares
Security Type: Common Stock
Securities Offered: 444,822,153
Price\Range: AUD 0.0115
Discount Per Security: AUD 0.00069
Transaction Features: Subsequent Direct Listing Annuncio • Oct 29
Cann Group Limited, Annual General Meeting, Nov 28, 2025 Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australia Reported Earnings • Aug 31
Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024) Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024). Board Change • Aug 18
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Peter Kopanidis was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Apr 14
Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 41,876,573
Price\Range: AUD 0.017
Discount Per Security: AUD 0.00102
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Annuncio • Apr 08
Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 41,876,573
Price\Range: AUD 0.017
Discount Per Security: AUD 0.00102
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Annuncio • Mar 12
Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million. Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 7,000,000
Price\Range: AUD 0.015
Transaction Features: Subsequent Direct Listing Annuncio • Dec 06
Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million. Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,724,489
Price\Range: AUD 0.04
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,675,343
Price\Range: AUD 0.04
Security Features: Attached Options
Transaction Features: Rights Offering Annuncio • Oct 09
Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million. Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 156,312,161
Price\Range: AUD 0.04
Security Features: Attached Options
Transaction Features: Rights Offering Annuncio • Sep 03
Cann Group Limited, Annual General Meeting, Oct 28, 2024 Cann Group Limited, Annual General Meeting, Oct 28, 2024. Reported Earnings • Sep 01
Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023) Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings. Annuncio • Jul 24
Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024 Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024 Board Change • Jun 05
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Mar 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$20m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€16.3m market cap, or US$17.7m). Annuncio • Aug 29
Cann Group Limited, Annual General Meeting, Oct 26, 2023 Cann Group Limited, Annual General Meeting, Oct 26, 2023, at 10:00 AUS Eastern Standard Time. Reported Earnings • Aug 28
Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022) Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. New Risk • Aug 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$35m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€31.6m market cap, or US$34.2m). Annuncio • Jul 26
Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million. Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 97,153,716
Price\Range: AUD 0.12
Discount Per Security: AUD 0.0024
Security Features: Attached Options
Transaction Features: Rights Offering Annuncio • Jul 06
Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023 Cann Group Limited provided revenue guidance for the year ended June 30, 2023. Cann expects to report unaudited product sales revenue of approximately $13.5 million, before accounting for services, for the 12 months ending 30 June 2023 representing a 111% increase on FY22 revenue ($6.4 million). Strong market demand saw revenue from the sale of dried flower products increase by approximately 500% on FY22 and is the base for continued growth as the company scales up production. This improvement was driven by the domestic market, with the strong sales momentum supported by new clients entering into supply agreements, and several existing clients with repeat orders. Customer acquisition has been strengthened by Cann's ability to supply consistent quality, GMP product from the flagship facility in Mildura, achieved through state- of-the-art cultivation and manufacturing processes. FY23 production output at Mildura was 2.2 tonnes. In May 2023, Cann planted the largest crop in the Company's history, representing 8 tons annualised yield. This crop will be harvested in July 2023. Reported Earnings • Feb 26
First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022) First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Annuncio • Jan 20
Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical Trail Cann Group Limited announced preliminary results from their Phase 3 clinical trail. Trial compared the efficacy of low dose Satipharm® CBD capsules to placebo in treating sleep disturbances. Three doses of Satipharm® CBD capsules were compared to placebo in a randomised, double-blind, placebo-controlled, multicentre clinical trial that included a total of 257 participants with sleep disturbances. Preliminary view of the analysis of the primary end-points have not shown a statistically superior response compared to placebo. Cann Group expects these trial results will delay submission of the registration application to the Therapeutic Goods Administration (TGA) for this indication. Once the full data set (including the secondary end-points) and report of the clinical trial is delivered to the company, Cann Group will evaluate the data and review its approach for this indication. A market update will be published once that review is complete. Annuncio • Jan 10
Cann Group Limited Announces Chief Executive Officer Changes Cann Group Limited announced that Peter Koetsier has been appointed to the role of Chief Executive Officer (CEO) and will commence in the role on January 16, 2023. Mr. Koetsier will replace Peter Crock, who was appointed on April 19, 2016 and announced on October 24, 2022 that he would be stepping down as CEO of the Company. Mr. Koetsier brings to Cann more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies. He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands. Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK, and Bristol-Myers Squibb in Europe. Mr. Koetsier has a bachelor's degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 30
Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021) Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021). Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 21
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: AU$0.028 loss per share (up from AU$0.05 loss in 1H 2021). Net loss: AU$8.28m (loss narrowed 12% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 277%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Executive Departure • Sep 07
Chief Financial Officer Greg Bullock has left the company During their tenure, earnings grew by 46% annually compared to the industry average of 8.2%. On the 1st of September, Greg Bullock left the company after 1.3 in the role. We don't have any record of a personal shareholding under Greg's name. Greg is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model. Reported Earnings • Aug 24
Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020) Full year 2021 results: Net loss: AU$25.1m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 24
First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020) First half 2021 results: Net loss: AU$9.40m (loss widened 12% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 41% per year whereas the company’s share price has fallen by 39% per year. Is New 90 Day High Low • Feb 10
New 90-day high: €0.52 The company is up 167% from its price of €0.19 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period. Is New 90 Day High Low • Nov 24
New 90-day high: €0.30 The company is up 21% from its price of €0.25 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Is New 90 Day High Low • Oct 12
New 90-day low: €0.23 The company is down 54% from its price of €0.50 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period. 